U.S. markets closed

Merck & Co., Inc. (MRK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
76.27+0.13 (+0.17%)
At close: 4:02PM EDT
Sign in to post a message.
  • J
    John
    MRK have tested the therapeutic treatment on only 1,500 patients! They need to do 10 times this off to prove if it works.
  • g
    greg
    From the CEO Last week - The $MRK COMBO DATA IS SPECTACULAR - baby bio about to grow up about to be a billion dollar co.
    ‘There seems to be true and strong pharmacodynamic and - biological synergy between our lead asset, galinpepimut-S (GPS) and checkpoint inhibitor drugs. We are very pleased that we received notice of allowance of our patent application for this combination approach - could aim up to 20 indications and we look forward to providing further data from our study of GPS in combination with pembrolizumab in patients with 2nd or 3rd line relapsed/refractory metastatic ovarian cancer, as well as the study of GPS in combination with nivolumab in relapsed/refractory MPM later this quarter. The patent application is expected to be granted on June 15, 2021, as U.S. Patent No. 11,033,613. Really great work by our legal and clinical folks further strengthening our IP portfolio.
  • M
    Mike3333
    Analysts say that the one year target price is $93. I don't understand this, it should be at least $80 now.
    I bought 300 shares at $74, should I sell or add more around $70.
    Neutral
  • B
    Bjarne
    Let me guess, pharma is on a roll due to inflation fears? :-)
    Bullish
  • A
    Anonymous
    With this down trend, something is wrong with Merck. Without insider stories, look at technical chart. It shows the stock is testing low again, next level at $71.5, then next at $69.5. Not pretty.
  • A
    Anonymous
    The excitement of spinoff is over. Did shareholders gain? No. Does the company operate more efficiently without this unit? I did not see it. Management needs to focus on efficiency, rather than playing games in financial number.
  • R
    Rob_Chemist
    Cost basis adjustment after the spin-off. For those who held MRK shares before the OGN spin-off, the new cost basis is as follows (based on TD Ameritrade). The cost basis of the MRK shares is reduced by 5%. The cost basis for the OGN shares is 5% of the price you paid for the MRK shares times 10. So, if you hold some MRK shares you bought at $80 prior to the spin-off, your new cost basis for MRK is $76 per share while the cost basis for OGN is $40 per share. I hope that this helps.
  • J
    John
    MRK struck $1.2B COVID-19 deal which is awesome. $80-$85 is coming!
  • J
    John
    Likely FDA will approve Merk Therapeutic treatment and on that day MRK could shoot $15 - $20. I am waiting for that day to happen!
  • g
    greg
    Analysts enjoyed having Thursdays commentary - easier in print, you can see the ceo told everyone the $mrk Keytruda data is worth billions.
  • J
    John
    $1.2B deal to begin with is nothing guys, when the FDA approves it MRK will fly over $100 just like NVAX/MRNA/BNTX
  • M
    MAI
    I had Merck shares bought on May 27th, can I receive Oganon shares? I spoke to RBC direct investing, they said I have to call Merck to figure out about this. Can some one advise how can I get cost adjustment from Merck as I have 600 shares as of today? Many thanks
    Neutral
  • H
    Howie
    RBC takes its price target to 75 from 77 to reflect OGN spin off....😂👌
  • S
    Simon
    Am I the only one who didn't get any cash from the organon spin-off of my fractional shares? any help?
  • H
    Howie
    let's just remind folks that you shouldn't believe all you read on a message board. Go to the source of the information for solid answers
  • H
    HvR
    This stock is stable. Do not panic sell when there's a day off.
  • G
    G
    Now is the time to ADD to your holdings..........Strong growth is on the Horizon.God Luck longs & Retirees .. imho
    Bullish
  • J
    John
    Today's news is the best news for MRK that I have ever seen on their real therapeutic treatment for all ages and FDA approved it! The world wide distribution will be announced soon!
  • g
    greg
    $SLS conversation
    From the CEO Last week - The $MRK COMBO DATA IS SPECTACULAR - 8:30 AM Tomorrow
    There seems to be true and strong pharmacodynamic and - biological synergy between our lead asset, galinpepimut-S (GPS) and checkpoint inhibitor drugs. We are very pleased that we received notice of allowance of our patent application for this combination approach - could aim up to 20 indications and we look forward to providing further data from our study of GPS in combination with pembrolizumab in patients with 2nd or 3rd line relapsed/refractory metastatic ovarian cancer, as well as the study of GPS in combination with nivolumab in relapsed/refractory MPM later this quarter. The patent application is expected to be granted on June 15, 2021, as U.S. Patent No. 11,033,613. Really great work by our legal and clinical folks further strengthening our IP portfolio.
  • S
    Seonjae
    If I have Merck shares bought by June 2nd, can I receive Oganon shares?
    Bullish